Unicycive Therapeutics, Inc. (UNCY): Shareholders' Equity

Annual figures by period end, from SEC filings.

$30.20M
As of 2025-12-31
$53.27M
As of 2026-06-30
2020-12-31: -$2.67M2021-12-31: $16.48M2022-12-31: -$466.0K2023-12-31: -$3.81M2024-12-31: $7.43M2025-12-31: $30.20M$30.20M
2020-12-31 Shareholders' Equity (USD) 2025-12-31
Period endedShareholders' EquityChange YoYSource filing
2025-12-31$30.20M+306.4%2026-03-30, Balance as of period end
2024-12-31$7.43Mn/m2026-03-30, Balance as of period end
2023-12-31-$3.81Mn/m2025-03-31, Balance as of period end
2022-12-31-$466.0Kn/m2024-03-28, Balance as of period end
2021-12-31$16.48Mn/m2023-03-31, Balance as of period end
2020-12-31-$2.67Mn/a2022-03-31, Balance as of period end

Shareholders' Equity at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedShareholders' EquityChange YoY
Unicycive Therapeutics, Inc. (UNCY)2025-12-31$30.20M+306.4%
Vistagen Therapeutics, Inc. (VTGN)2026-03-31$35.52M-49.5%
Coya Therapeutics, Inc. (COYA)2025-12-31$43.03M+8.7%
NextCure, Inc. (NXTC)2025-12-31$34.94M-46.6%
Opus Genetics, Inc. (IRD)2025-12-31$15.35M+128.3%
Akari Therapeutics Plc (AKTX)2025-12-31$28.33M+27.4%
Atossa Therapeutics, Inc. (ATOS)2025-12-31$39.35M-44.9%
Verrica Pharmaceuticals Inc. (VRCA)2025-12-31$24.74Mn/m
Actinium Pharmaceuticals, Inc. (ATNM)2025-12-31$7.83M-76.1%

Compare UNCY, VTGN, COYA, NXTC side by side · Screen every company in Pharmaceutical Preparations ↗